Matrix Capital Management
Matrix Capital Management is an employee-owned hedge fund sponsor focused on public equity markets.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Matrix Capital Management Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Matrix Capital Management is an investment management firm which manages private investment funds in a concentrated portfolio of high conviction investments, primarily in public companies. Matrix Capital was co-founded in 1999 by David Goel and is based outside of Boston, Massachusetts.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2020 | nference | Series B | 0 |
| 2/2021 | Anumana | Series A | 25.7M |
| 6/2018 | nference | Series A | 12M |
| 5/2021 | Anumana | Series B | 60M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 1/2022 | Solve Therapeutics | Series A | 126M |
| 8/2022 | Monod Bio | Seed Round | 0 |
| 1/2022 | Blockdaemon | Series C | 0 |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2022 | ReCode Therapeutics | Series B | 0 |
| 6/2023 | AltPep | Series B | 0 |
| 8/2021 | GentiBio | Series A | 157M |
| 1/2022 | Maze Therapeutics | Venture Round | 0 |
| 2/2022 | Koneksa Health | Series C | 0 |
| 11/2021 | ACELYRIN | Series B | 0 |
| 5/2022 | Talos | Series B | 0 |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 5/2021 | Emboline | Series D | 0 |
| 1/2016 | nference | Seed Round | 3M |
| 7/2017 | Qrativ | Series A | 8.3M |
| 9/2020 | Palleon Pharmaceuticals | Series B | 100M |
| 9/2022 | ACELYRIN | Series C | 0 |
| 12/2020 | nference | Series C | 0 |
| 10/2021 | Bardavon Health Innovations | Series C | 0 |
| 2/2016 | EpiBiome | Series A | 6M |
| 1/2022 | Pramana | Series A | 30M |
| 5/2023 | ElevateBio | Series D | 0 |
| 1/2022 | Alumis | Series B | 0 |
| 10/2013 | Xero | Post-IPO Equity | 150M |
| 2/2015 | Xero | Post-IPO Equity | 110.8M |
| 3/2021 | ElevateBio | Series C | 525M |
| 8/2000 | Tenor Networks | Series C | 93M |
| 7/2020 | Encoded Therapeutics | Series D | 0 |
| 9/2021 | Blockdaemon | Series B | 0 |
| 5/2015 | Adaptive Biotechnologies | Series F | 195M |
| 7/2020 | VelosBio | Series B | 137M |
| 11/2012 | Xero | Post-IPO Equity | 49M |
| 5/2023 | ElevateBio | Series D | 0 |
| 9/2022 | ACELYRIN | Series C | 0 |
| 8/2022 | Monod Bio | Seed Round | 0 |
| 6/2022 | ReCode Therapeutics | Series B | 0 |
| 5/2022 | Talos | Series B | 0 |
| 2/2022 | Koneksa Health | Series C | 0 |
| 1/2022 | Blockdaemon | Series C | 0 |
| 1/2022 | Solve Therapeutics | Series A | 0 |
| 1/2022 | Maze Therapeutics | Venture Round | 0 |
| 1/2022 | Alumis | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
